Table 2

Comparison of HRs obtained applying two analytic models (standard analysis vs GM) by settings

	Chronic kidney disease setting							Oncology setting
	Standard analysis			GM analysis				Standard analysis			GM analysis
	Biosimilars vs epoetin α originator			Biosimilars vs epoetin α originator				Biosimilars vs epoetin α originator			Biosimilars vs epoetin α originator
	HR_adj	LCI95%	UCI95%	HR_GM	LCI95%	UCI95%		HR_adj	LCI95%	UCI95%	HR_GM	LCI95%	UCI95%
Composite outcome	1.02	0.78	1.33	0.85	0.60	1.20	Composite outcome	0.91	0.79	1.06	0.85	0.71	1.01
All-cause mortality	0.92	0.67	1.28	0.70	0.47	1.06	All-cause mortality	0.82	0.70	0.97	0.76	0.62	0.93
Blood transfusion	0.95	0.54	1.69	1.11	0.50	2.48	Blood transfusion	1.06	0.82	1.35	1.10	0.80	1.51
MACE	0.92	0.49	1.70	0.95	0.41	2.19	MACE	0.84	0.48	1.47	0.90	0.44	1.82
Blood dyscrasia	1.19	0.74	1.92	1.19	0.61	2.35	Blood dyscrasia	0.86	0.66	1.14	0.83	0.59	1.16

	Biosimilars vs other originators			Biosimilars vs other originators				Biosimilars vs other originators			Biosimilars vs other originators
	HR_adj	LCI95%	UCI95%	HR_GM	LCI95%	UCI95%		HR_adj	LCI95%	UCI95%	HR_GM	LCI95%	UCI95%
Composite outcome	1.09	0.85	1.41	1.25	0.86	1.82	Composite outcome	1.01	0.88	1.16	0.96	0.80	1.15
All-cause mortality	1.00	0.73	1.38	1.19	0.75	1.88	All-cause mortality	1.01	0.86	1.18	0.95	0.77	1,17
Blood transfusion	0.99	0.57	1.71	0.81	0.39	1.68	Blood transfusion	0.98	0.77	1.23	0.96	0.71	1,31
MACE	1.08	0.60	1.97	1.65	0.64	4.26	MACE	0.79	0.46	1.35	0.71	0.37	1,38
Blood dyscrasia	1.26	0.80	1.99	1.13	0.59	2.18	Blood dyscrasia	0.86	0.66	1.12	0.82	0.59	1,14

adj, adjusted; GM, genetic matched; LCI, lower CI value; MACE,major cardiovascular events; UCI, upper CI value.